CureBay, a technology enabled primary healthcare operator focused on smaller towns and rural districts, announced a fresh financing package of roughly Rs 100 crore on October 22, 2026. The transaction, led by IvyCap Ventures and structured as a mix of equity and debt, will fund an accelerated roll out of physical clinics, expansion into southern India, and further development of the companys AI driven screening and clinical decision tools. Founded in 2021, CureBay combines community level health workers, neighborhood clinics, teleconsultations and logistics for diagnostics and medicines. The startup says it currently operates more than 250 technology enabled clinics across seven states, and supports those sites with a field force of community health workers and a network of partner doctors, laboratories and hospitals. Management told investors that the new capital will help scale the clinic footprint toward a planned network of several hundred additional sites over the next two years. H2: Deal structure and immediate priorities The financing comprises about Rs 69 crore of fresh equity led by IvyCap Ventures, with participation from existing backers, plus more than Rs 30 crore of debt provided by speciality lenders. Lenders named in reporting include Trifecta Capital, Alteria Capital and VentureSoul Partners. Company executives said equity will be used for clinic expansion, hiring and product development, while debt will support working capital needs tied to an expanding on the ground network. CureBay has also signalled a targeted geographic push, with management prioritising entry into Andhra Pradesh and Telangana to complement their existing presence in eastern and central India. Executives described those southern markets as attractive because of large underserved rural populations and high unmet primary care needs. H2: Technology and clinical roadmap A central pillar of CureBays pitch to investors is its combination of physical access and machine assisted screening. The company said it will invest in an intelligence layer to improve population level screening, risk stratification and frontline clinical decision support. Existing screening modules include checks for common conditions such as anemia, diabetes risk, and basic dermatology. Investors told reporters they are backing both capex for clinics and product engineering to progressively automate routine screening and referral pathways. CureBay argues the blended model addresses a persistent gap in India: many rural patients lack convenient, reliable primary care, while urban centric digital clinics struggle to reach last mile communities. The model pairs a community health worker at the doorstep with a clinic that can provide point of care tests, teleconsults with doctors, and organised referrals when higher level care is needed. H2: Financial position and growth targets Public reporting and company commentary state CureBay closed fiscal year 2026 with annual recurring revenue in the region of Rs 170 crore, and that the management team expects to roughly double that run rate over the next 12 months through clinic expansion and higher utilisation. Company filings were not immediately available for independent audit of those figures. Management also said the business had reached operating EBITDA break even in the most recent period, even while remaining loss making at the consolidated level as it invests to scale. Investors highlighted the unit economics improvements the company has demonstrated, citing better average revenue per clinic and lower patient acquisition costs as the network matures. Still, converting revenue momentum into company level profitability will depend on managing the capital intensity of opening clinics, maintaining quality across a distributed model, and passing regulatory and local provider credentialing hurdles in new states. H2: Why the round matters for Indias rural health market The transaction underlines continuing investor appetite for healthtech models that combine technology with last mile physical presence. In recent years, venture capital in India has flowed into both pure digital telemedicine services and hybrid clinic networks. CureBays raise is notable because it is structured with a mix of equity and debt, reflecting growing use of non dilutive capital to finance working capital heavy expansions in sectors such as healthcare. For policymakers and large healthcare players, CureBays strategy is a proof point for a decentralised primary care approach. If the company can scale without eroding clinical quality, the model could reduce unnecessary hospital visits, improve early detection of chronic conditions, and relieve pressure on tertiary centres. For investors, the investment signals belief that unit economics in rural primary care can meaningfully improve when digital tools and community agents are integrated into a single operating system. H2: Near term risks and milestones Key milestones to watch include CureBays ability to enter Andhra Pradesh and Telangana swiftly while managing regulatory and provider on boarding, progress on AI screening modules and clinical validation, and monthly clinic unit economics as the network grows. Risks include operational execution across dispersed rural geographies, competition from larger chains and regional providers, and potential reimbursement or regulatory changes affecting telemedicine and diagnostics. CureBays Rs 100 crore pre Series C round positions the startup for a more ambitious scale up phase. The coming 12 months should make clearer whether the hybrid model can convert stronger revenue growth into sustainable, company level profitability while maintaining the clinical standards needed to serve rural India effectively.